Streetbeat News

Equity Actions

EW

Analysts have provided diverse perspectives on Edwards Lifesciences (NYSE:EW), with 14 ratings in the last three months. The average 12-month price target is now $78.5, down 11.62% from the previous $88.82. Analysts have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Edwards Lifesciences, known for its medical devices for structural heart disease, has shown a revenue growth of 12.27% and strong financial health with high net margin and ROE. However, its revenue growth lags behind industry peers.

Portfolio Pulse from Benzinga Insights

December 22, 2023 | 3:01 pm

ROST

Ross Stores (NASDAQ:ROST) received mixed ratings from 8 financial analysts, with an average 12-month price target of $138.12, up from $132.60. Analysts from firms like Wells Fargo, BMO Capital, Morgan Stanley, Telsey Advisory Group, Evercore ISI Group, and Gordon Haskett have raised their price targets, reflecting a positive outlook on the company's performance. Ross Stores has shown solid revenue growth, exceptional net margin, and impressive ROE and ROA, with a prudent approach to debt management.

Portfolio Pulse from Benzinga Insights

December 22, 2023 | 3:01 pm

VSCO

Victoria's Secret (NYSE:VSCO) has received mixed analyst ratings over the past three months, with the majority being indifferent. The average 12-month price target for VSCO has increased by 17.35% to $23.00, with a high estimate of $29.00 and a low of $16.00. Analysts from firms like Wells Fargo, Morgan Stanley, Telsey Advisory Group, BMO Capital, and Evercore ISI Group have updated their ratings and price targets, reflecting their views on the company's market performance. Victoria's Secret's financial performance shows a market cap below industry average, a revenue decline of -4.02%, low net margin, ROE, and ROA, and a high debt-to-equity ratio, indicating potential challenges ahead.

Portfolio Pulse from Benzinga Insights

December 22, 2023 | 3:01 pm

CYCC

Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) shares dropped 26.9% after announcing a registered direct offering of 388,200 shares at $3.315 each, and a concurrent private placement to management. Warrants are also being issued, exercisable at $3.19 for seven years. Ladenburg Thalmann & Co. Inc. is managing the offering, which aims to raise about $1.3 million for general corporate purposes. The offering is expected to close on December 26, subject to standard conditions.

Portfolio Pulse from Henry Khederian

December 22, 2023 | 2:36 pm

IMPP

Imperial Petroleum Inc. has announced that Flawless Management Inc. converted all 13,875 shares of its Series C Cumulative Convertible Perpetual Preferred Stock into 6,932,043 shares of Imperial Petroleum's Common Stock.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 2:21 pm

CYCC

CYCCP

Cyclacel Pharmaceuticals, Inc. has announced a registered direct offering of 388,200 shares and a private placement of 7,956 shares, both at $3.315 per share. Additionally, warrants to purchase up to 396,156 shares at $3.19 per share are being issued. The closing is expected around December 26, 2023, with Ladenburg Thalmann & Co. Inc. as the placement agent.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 2:19 pm

ELTX

Elicio Therapeutics has completed a private placement financing round, raising $7 million through the sale of 1.213 million shares at a price of $5.81 per share.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 2:05 pm

SEZL

Sezzle Inc. has announced a $5 million stock repurchase program, signaling the Board's belief that the current share price undervalues the company. CEO Charlie Youakim emphasized the move as a step towards maximizing shareholder value, indicating confidence in the company's performance and considering the repurchase a suitable use of capital resources.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 2:03 pm

SIG

Analysts have mixed views on Signet Jewelers (NYSE:SIG), with recent ratings ranging from bullish to bearish. Over the last quarter, there were 1 bullish, 2 somewhat bullish, and 2 indifferent ratings. The average 12-month price target is $104.2, up from $96.25, with a high of $120 and a low of $82. Wells Fargo and Citigroup raised their targets, while Telsey Advisory Group raised and maintained theirs. Signet's financials show a -12.06% revenue decline over 3 months, but strong profitability with a net margin of 0.22% and high ROE of 0.19%. The company's debt-to-equity ratio is healthy at 0.81.

Portfolio Pulse from Benzinga Insights

December 22, 2023 | 2:00 pm

GPS

Gap Inc. (NYSE:GPS) has received diverse ratings from 9 financial analysts over the last three months, with a shift towards more bullish sentiment in the last 30 days. The average 12-month price target is $16.78, up 27.7% from the previous $13.14, with a high estimate of $24.00 and a low of $11.00. Analysts from firms including Wells Fargo, BMO Capital, Goldman Sachs, Morgan Stanley, Telsey Advisory Group, and Evercore ISI Group have raised their price targets and ratings, indicating a positive outlook on Gap's performance. Despite a -6.73% decline in revenue over 3 months, Gap maintains a strong net margin of 5.79%, an ROE of 9.23%, and an ROA of 1.99%, with a low debt-to-equity ratio of 2.26.

Portfolio Pulse from Benzinga Insights

December 22, 2023 | 2:00 pm